Trial reportCPT: pharmacometrics & systems pharmacology2020
Exposure-Safety Analyses Identify Predictors of Change in Bone Mineral Density and Support Elagolix Labeling for Endometriosis-Associated Pain.
Trial report in CPT: pharmacometrics & systems pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.Inflammopharmacology · 2026Review
- Role of Epigenetic Modifications in The Aberrant Expression of TheInternational journal of fertility & sterility · 2026Article
- The Multifactorial Pathogenesis of Endometriosis: A Narrative Review Integrating Hormonal, Immune, and Microbiome Aspects.Medicina (Kaunas, Lithuania) · 2025Review
- Breaking the silence: The role of extracellular vesicles in unraveling the diagnosis and treatment of endometriosis.Extracellular vesicles and circulating nucleic acids · 2023Review
- Interdisciplinary model-informed drug development for extending duration of elagolix treatment in patients with uterine fibroids.British journal of clinical pharmacology · 2022Article
- Endometriosis: Epidemiology, Classification, Pathogenesis, Treatment and Genetics (Review of Literature).International journal of molecular sciences · 2021Review
- HOX cluster and their cofactors showed an altered expression pattern in eutopic and ectopic endometriosis tissues.Reproductive biology and endocrinology : RB&E · 2021Article
- Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.Clinical and translational science · 2021Article
- Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.Expert review of clinical pharmacology · 2021Review
- A Personalized Medicine Approach Using Clinical Utility Index and Exposure-Response Modeling Informed by Patient Preferences Data.CPT: pharmacometrics & systems pharmacology · 2021Article
- Computational Models for Diagnosing and Treating Endometriosis.Frontiers in reproductive health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Elagolix is a novel oral gonadotropin releasing hormone receptor antagonist, that can suppress estradiol in a dose-dependent manner. It is indicated for management of moderate-to-severe pain associated with endometriosis. A population exposure-response model describing the relationship between elagolix exposure and changes in bone mineral density (BMD) was developed using data from four phase III studies in premenopausal women with endometriosis-associated pain. Elagolix pharmacokinetic exposure-dependent changes in BMD were described by an indirect-response maximum effect (E
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.